Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States

ClinicoEconomics and Outcomes Research

Volumn 5, Issue 1, 2013, Pages 101-108

  Khorana, Alok A ^a   Dalal, Mehul R ^b   Lin, Jay ^c   Connolly, Gregory C ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b SANOFI   (France)

^c Novosys Health   (United States)

Author keywords

Cancer; Cohort study; Health care costs; Resource utilization; Venous thromboembolism

Indexed keywords

ADULT; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HIGH RISK PATIENT; HUMAN; LENGTH OF STAY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PANCREAS CANCER; SOLID TUMOR; STOMACH CANCER; UNITED STATES; VENOUS THROMBOEMBOLISM;

EID: 84874292191     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S39964     Document Type: Article

References (41)

1. Noble S, Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer. 2010;102 Suppl 1:S2-S9.
2. Kessler CM. The link between cancer and venous thromboembolism: a review. Am J Clin Oncol. 2009;32:S3-S7.
3. Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol. 2009;27:4839-4847.
4. Geerts WH, Bergqvist D, Pineo GF, etal. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed). Chest. 2008;133: 381S-453S.
5. Heit JA, Silverstein MD, Mohr DN, etal. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160:809-815.
6. Lip GY, Chin BS, Blann AD. Cancer and the prothrombotic state. Lancet Oncol. 2002;3:27-34.
7. De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol. 2004;50:187-196.
8. Lyman GH, Khorana AA, Falanga A, etal. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25:5490-5505.
9. Levitan N, Dowlati A, Remick SC, etal. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999;78:285-291.
10. Prandoni P, Lensing AW, Piccioli A, etal. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002; 100:3484-3488.
11. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost. 2002;87:575-579.
12. Khorana AA, Francis CW, Culakova E, etal. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol. 2006;24: 484-490.
13. Blom JW, Doggen CJ, Osanto S, etal. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293: 715-722.
14. Blom JW, Vanderschoot JP, Oostindier MJ, etal. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost. 2006;4:529-535.
15. Stein PD, Beemath A, Meyers FA, etal. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. 2006;119: 60-68.
16. Agnelli G, Bolis G, Capussotti L, etal. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg. 2006;243:89-95.
17. Wun T, White RH. Epidemiology of cancer-related venous thromboembolism. Best Pract Res Clin Haematol. 2009;22:9-23.
18. Elting LS, Escalante CP, Cooksley C, etal. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med. 2004;164:1653-1661.
19. Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30managed care organizations. J Manag Care Pharm. 2007;13:475-486.
20. Amin AN, Lin J, Yang G, etal. Are there any differences in the clinical and economic outcomes between US cancer patients receiving appropriate or inappropriate venous thromboembolism prophylaxis? J Oncol Pract. 2009;5:159-164.
21. Harrington KJ, Bateman AR, Syrigos KN, etal. Cancer-related thromboembolic disease in patients with solid tumours: a retrospective analysis. Ann Oncol. 1997;8:669-673.
22. Spyropoulos AC, Hussein M, Lin J, etal. Rates of symptomatic venous thromboembolism in US surgical patients: a retrospective administrative database study. J Thromb Thrombolysis. 2009;28:458-464.
23. Baser O. Too much ado about propensity score models? Comparing methods of propensity score matching. Value Health. 2006;9:377-385.
24. Charlson ME, Pompei P, Ales KL, etal. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
25. Quan H, Sundararajan V, Halfon P, etal. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130-1139.
26. Khorana AA, Kuderer NM, Culakova E, etal. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902-4907.
27. MacDougall DA, Feliu AL, Boccuzzi SJ, etal. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health Syst Pharm. 2006;63:S5-S15.
28. Dobesh PP. Clopidogrel versus prasugrel: times are changing, but not for everyone. Pharmacotherapy. 2009;29:1393-1396.
29. Lee AY. Thrombosis in cancer: an update on prevention, treatment, and survival benefits of anticoagulants. Hematology Am Soc Hematol Educ Program. 2010;2010:144-149.
30. Stanley A, Young A. Primary prevention of venous thromboembolism in medical and surgical oncology patients. Br J Cancer. 2010;102 Suppl 1:S10-S16.
31. Khorana AA, Dalal M, Tangirala K, etal. Higher incidence of venous thromboembolism in the outpatient versus the inpatient setting among US cancer patients. Abstract 674 presented at the 53rd American Society of Hypertension. San Diego, CA, December 10-13, 2011.
32. Ay C, Dunkler D, Marosi C, etal. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116:5377-5382.
33. Ay C, Vormittag R, Dunkler D, etal. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2009;27:4124-4129.
34. Ay C, Simanek R, Vormittag R, etal. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood. 2008;112:2703-2708.
35. Kroger K, Weiland D, Ose C, etal. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol. 2006;17:297-303.
36. Uno K, Homma S, Satoh T, etal. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer. 2007; 96:290-295.
37. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Venous thromboembolic disease, 2011.
38. Agnelli G, Gussoni G, Bianchini C, etal. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009;10: 943-949.
39. Riess H, Pelzer U, Deutschinoff G, etal. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): results of the CONKO 004 trial. J Clin Oncol. 2009;27(Suppl 18):Abstract LBA4506.
40. Maraveyas A, Holmes M, Lofts F, etal. Chemoanticoagulation versus chemotherapy in advanced pancreatic cancer (APC): Results of the interim analysis of the FRAGEM trial. J Clin Oncol. 2007;25(Part I, Suppl 18):Abstract 4583.
41. Agnelli G, George DJ, Kakkar AK, etal. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366:601-609.